Phase 1 Lymphoma Trial, Recruiting NCT05277753 Sponsor: Shenzhen Geno-Immune Medical Institute Condition: Lymphoma
Back to Lymphoma

Phase 1 Lymphoma Trial, Recruiting

NCT05277753
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People older than 6 months of age.
  • People whose bone marrow sample shows a high number of abnormal (cancer) cells — at least 30% — which is needed for certain laboratory testing and treatment preparation.
  • People whose cancer cells show certain specific proteins on their surface (such as CD7, CD5, CD317, CD47, CD99, CD38, or TRBC1/2), as detected by laboratory testing.
  • People who are in reasonably good general health, as measured by a standard health scoring system, and whose life expectancy is greater than 3 months.
  • People whose heart, liver, kidneys, and bone marrow are functioning well enough to meet specific laboratory test thresholds — including heart pumping function of at least 50%, blood oxygen level of at least 90%, and kidney and liver values within acceptable ranges.
  • People whose blood haemoglobin (a measure of red blood cell health) is at an acceptable level (at least 80g/L).
  • People who have no medical reasons preventing a cell separation procedure.
  • People who are able to understand the study and are willing to sign a written consent form.

Who may not be able to join:

  • People with a serious illness or medical condition that would make it unsafe to follow the trial procedures, including those with an active infection that is not under control.
  • People with an active bacterial, fungal, or viral infection that has not been controlled with treatment.
  • People with a known diagnosis of HIV, hepatitis B, or hepatitis C.
  • People who are pregnant or breastfeeding.
  • People who have used steroid (glucocorticoid) medications as a whole-body (systemic) treatment within the week before entering the trial.
  • People who have previously received any gene therapy treatment.
  • People who the trial investigators believe may not be suitable or may not be able to follow the trial requirements (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 0755-86573763

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Shenzhen Geno-Immune Medical Institute
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
31 December 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Treatment-related adverse events are assessed by NCI CTCAE V4.0 criteria.; Clinical response; Evaluate the percentage of minimal leukemia residue in bone marrow

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov